Beneficial metabolic effects caused by persistent activation of β-cell M3 muscarinic acetylcholine receptors in transgenic mice

Endocrinology

Volumn 151, Issue 11, 2010, Pages 5185-5194

  Gautam, Dinesh ^a   De Azua, Inigo Ruiz ^a   Li, Jian Hua ^a   Guettier, Jean Marc ^a   Heard, Thomas ^a   Cui, Yinghong ^a   Lu, Huiyan ^a   Jou, William ^a   Gavrilova, Oksana ^a   Zawalich, Walter S ^b   Wess, Jürgen ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b YALE UNIVERSITY SCHOOL OF NURSING   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATROPINE; GLUCOSE; INSULIN; MUSCARINIC M3 RECEPTOR; MUSCARINIC RECEPTOR BLOCKING AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL ACTIVATION; CELL ISOLATION; CONTROLLED STUDY; GLUCOSE INTOLERANCE; HYPERGLYCEMIA; HYPERINSULINEMIA; HYPOGLYCEMIA; IN VITRO STUDY; IN VIVO STUDY; INSULIN BLOOD LEVEL; MALE; MOUSE; NONHUMAN; PANCREAS ISLET BETA CELL; PHENOTYPE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; ANALYSIS OF VARIANCE; ANIMAL; BLOOD; DRUG EFFECT; GENETICS; GENOTYPE; GLUCOSE BLOOD LEVEL; HOMEOSTASIS; METABOLISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SECRETION; TRANSGENIC MOUSE;

ANALYSIS OF VARIANCE; ANIMALS; ATROPINE; BLOOD GLUCOSE; GENOTYPE; HOMEOSTASIS; INSULIN; INSULIN-SECRETING CELLS; MICE; MICE, TRANSGENIC; MUSCARINIC ANTAGONISTS; PHENOTYPE; RECEPTOR, MUSCARINIC M3; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 78049521571     PISSN: 00137227     EISSN: 00137227     Source Type: Journal    
DOI: 10.1210/en.2010-0519     Document Type: Article

References (44)

1. Kahn CR 1994 Insulin action, diabetogenes, and the cause of type II diabetes. Diabetes 43:1066-1084
2. Kahn SE 2003 The relative contributions of insulin resistance and β-cell dysfunction to the pathophysiology of Type 2 diabetes. Diabetologia 46:3-19
3. Moller DE 2001 New drug targets for type 2 diabetes and the metabolic syndrome. Nature 414:821-827
4. Satin LS, Kinard TA 1998 Neurotransmitters and their receptors in the islets of Langerhans of the pancreas: what messages do acetylcholine, glutamate, and GABA transmit? Endocrine 8:213-223
5. Ahrén B 2000 Autonomic regulation of islet hormone secretion: implications for health and disease. Diabetologia 43:393-410
6. Gilon P, Henquin JC 2001 Mechanisms and physiological significance of the cholinergic control of pancreatic β-cell function. Endocr Rev 22:565-604
7. Ahrén B 2009 Islet G protein-coupled receptors as potential targets for treatment of type 2 diabetes. Nat Rev Drug Discov 8:369-385
8. 3 muscarinic acetylcholine receptor-deficient mice. Diabetes 53:1714-1720
9. Zawalich WS, Zawalich KC, Tesz GJ, Taketo MM, Sterpka J, Philbrick W, Matsui M 2004 Effects of muscarinic receptor type 3 knockout on mouse islet secretory responses. Biochem Biophys Res Commun 315:872-876
10. Henquin JC, Nenquin M 1988 The muscarinic receptor subtype in mouse pancreatic B-cells. FEBS Lett 236:89-92
11. Verspohl EJ, Tacke R, Mutschler E, Lambrecht G 1990 Muscarinic receptor subtypes in rat pancreatic islets: binding and functional studies. Eur J Pharmacol 178:303-311 (Pubitemid 20126669)
12. Karlsson S, Ahren BJ 1993 Muscarinic receptor subtypes in carbachol-stimulated insulin and glucagon secretion in the mouse. J Auton Pharmacol 13:439-446
13. Wess J 1996 Molecular biology of muscarinic acetylcholine receptors. Crit Rev Neurobiol 10:69-99
14. 3 muscarinic acetylcholine receptors in regulating insulin release and blood glucose homeostasis in vivo. Cell Metab 3:449-461
15. Böhm SK, Grady EF, Bunnett NW 1997 Regulatory mechanisms that modulate signalling by G-protein-coupled receptors. Biochem J 322:1-18
16. Krupnick JG, Benovic JL 1998 The role of receptor kinases and arrestins in G protein-coupled receptor regulation. Annu Rev Pharmacol Toxicol 38:289-319
17. Premont RT, Gainetdinov RR 2007 Physiological roles of G protein-coupled receptor kinases and arrestins. Annu Rev Physiol 69:511-534
18. van Koppen CJ, Kaiser B 2003 Regulation of muscarinic acetylcholine receptor signaling. Pharmacol Ther 98:197-220
19. q/11 in SH-SY5Y human neuroblastoma cells. Br J Pharmacol 134:257-264
20. 3 muscarinic acetylcholine receptor in human SH-SY5Y cells. Mol Pharmacol 60:321-330
21. 3 muscarinic acetylcholine receptor signaling. Mol Pharmacol 64:1059-1068
22. Fukamauchi F, Saunders PA, Hough C, Chuang DM 1993 Agonist-induced down-regulation and antagonist-induced up-regulation of m2- and m3-muscarinic acetylcholine receptor mRNA and protein in cultured cerebellar granule cells. Mol Pharmacol 44:940-949
23. Steel MC, Buckley NJ 1993 Differential regulation of muscarinic receptor mRNA levels in neuroblastoma cells by chronic agonist exposure: a comparative polymerase chain reaction study. Mol Pharmacol 43:694-701
24. Yang J, Logsdon CD, Johansen TE, Williams JA 1993 Human m3 muscarinic acetylcholine receptor carboxyl-terminal threonine resides are required for agonist-induced receptor down-regulation. Mol Pharmacol 44:1158-1164
25. 3 receptor and greatly impair receptor/G protein coupling. J Biol Chem 278:30248-30260
26. Vasavada RC, Cavaliere C, D'Ercole AJ, Dann P, Burtis WJ, Madlener AL, Zawalich K, Zawalich W, Philbrick W, Stewart AF 1996 Overexpression of parathyroid hormone-related protein in the pancreatic islets of transgenic mice causes islet hyperplasia, hyperinsulinemia, and hypoglycemia. J Biol Chem 271:1200-1208
27. Ahrén B, Sauerberg P, Thomsen C 1999 Increased insulin secretion and normalization of glucose tolerance by cholinergic agonism in high fat-fed mice. Am J Physiol 277:E93-102
28. Dörje F, Wess J, Lambrecht G, Tacke R, Mutschler E, Brann MR 1991 Antagonist binding profiles of five cloned human muscarinic receptor subtypes. J Pharmacol Exp Ther 256:727-733
29. Postic C, Shiota M, Niswender KD, Jetton TL, Chen Y, Moates JM, Shelton KD, Lindner J, Cherrington AD, Magnuson MA 1999 Dual roles for glucokinase in glucose homeostasis as determined by liver and pancreatic β cell-specific gene knock-outs using Cre recombinase. J Biol Chem 274:305-315
30. Gannon M, Shiota C, Postic C, Wright CV, Magnuson M 2000 Analysis of the Cre-mediated recombination driven by rat insulin promoter in embryonic and adult mouse pancreas. Genesis 26:139-142
31. Cui Y, Huang L, Elefteriou F, Yang G, Shelton JM, Giles JE, Oz OK, Pourbahrami T, Lu CY, Richardson JA, Karsenty G, Li C 2004 Essential role of STAT3 in body weight and glucose homeostasis. Mol Cell Biol 24:258-269
32. Spalding TA, Burstein ES, Brauner-Osborne H, Hill-Eubanks D, Brann MR 1995 Pharmacology of a constitutively active muscarinic receptor generated by random mutagenesis. J Pharmacol Exp Ther 275:1274-1279
33. 2 muscarinic acetylcholine receptor. J Pharmacol Exp Ther 316:279-288
34. Gao ZY, Gilon P, Henquin JC 1994 The role of protein kinase-C in signal transduction through vasopressin and acetylcholine receptors in pancreatic B-cells from normal mouse. Endocrinology 135:191-199
35. Johnson DE, Yamazaki H, Ward KM, Schmidt AW, Lebel WS, Treadway JL, Gibbs EM, Zawalich WS, Rollema H 2005 Inhibitory effects of antipsychotics on carbachol-enhanced insulin secretion from perifused rat islets. Role of muscarinic antagonism in antipsychotic-induced diabetes and hyperglycemia. Diabetes 54:1552-1558
36. Fukudo S, Virnelli S, Kuhn CM, Cochrane C, Feinglos MN, Surwit RS 1989 Muscarinic stimulation and antagonism and glucoregulation in nondiabetic and obese hyperglycemic mice. Diabetes 38:1433-1438
37. Berglund O 1980 Different dynamics of insulin secretion in the perfused pancreas of the mouse and rat. Acta Endocrinol 93:54-60
38. Lenzen S 1979 Insulin secretion by isolated perfused rat and mouse pancreas. Am J Physiol 236:E391-E400
39. Ma YH, Wang J, Rodd GG, Bolaffi JL, Grodsky GM 1995 Differences in insulin secretion between rat and mouse islets: role of cAMP. Eur J Endocrinol 132:370-376
40. Kiba T, Tanaka K, Numata K, Hoshino M, Misugi K, Inoue S 1996 Ventromedial hypothalamic lesion-induced vagal hyperactivity stimulates rat pancreatic cell proliferation. Gastroenterology 110:885-893
41. Eglen RM, Hegde SS, Watson N 1996 Muscarinic receptor subtypes and smooth muscle function. Pharmacol Rev 48:531-565
42. Caulfield MP, Birdsall NJM 1998 International Union of Pharmacology. XVII. Classification of muscarinic acetylcholine receptors. Pharmacol Rev 50:279-290
43. Wess J, Eglen RM, Gautam D 2007 Muscarinic acetylcholine receptors: mutant mice provide new insights for drug development. Nat Rev Drug Discov 6:721-733
44. Conn PJ, Jones CK, Lindsley CW 2009 Subtype-selective allosteric modulators of muscarinic receptors for the treatment of CNS disorders. Trends Pharmacol Sci 30:148-155